Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Catenacci, Daniel V.T.; Uronis, Hope E.; Kang, Yoon‐Koo; Lacy, Jill; Enzinger, Peter C.; Park, Se Hoon; Lee, Moon Hyoung; Ng, Matthew; Gold, Philip J.; Yen, Jennifer; Franovic, Aleksandra; Kelly, Ronan J.; Wynter-Horton, A.; Li, Daner; Muth, John; Baughman, Jan; Hong, Seong Wook; Davidson-Moncada, Jan K.; Bang, Yung‐Jue

doi:10.1200/jco.2018.36.15_suppl.4030

Cited by 14 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While these findings lay the groundwork for combination therapy, further studies will help to elucidate the mechanisms that underlie the immunomodulation of chemotherapeutic agents to optimize their potent effects with checkpoint inhibition. A number of studies have sought to evaluate the efficacy of checkpoint inhibitors in combination with chemotherapeutic agents or radiotherapy (43,(76)(77)(78). One phase II trial found the PD-L1 inhibitor LY3300054 (LY) alone or in combination with ramucirumab or merestinib in 38 patients with advanced, refractory solid tumors demonstrated antitumor activity with one partial response in each cohort (76).…”

Section: Discussionmentioning

confidence: 99%

Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies

Chuang

Chao

Hendifar

et al. 2019

Transl. Gastroenterol. Hepatol

View full text Add to dashboard Cite

The development of checkpoint inhibitors has redefined the treatment paradigm for advanced gastroesophageal cancer. While recent developments have improved clinical outcomes, the prognosis for the disease remains meager. In this review, we discuss the rationale and detail the results from recent phase I-III trials supporting the activity of PD-1 inhibitors. Specifically, we highlight the seminal clinical trials leading to the FDA approval of pembrolizumab for advanced gastroesophageal cancer. Finally, we review the current understanding and future considerations of molecular subtyping and predictive biomarkers to help guide therapy and the promise of combination therapy to further improve the efficacy of checkpoint inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies

Chuang

Chao

Hendifar

et al. 2019

Transl. Gastroenterol. Hepatol

View full text Add to dashboard Cite

show abstract

“…In terms of safety, an adverse reaction rate of grade 3 and above was 13%. No treatment-related deaths occurred (48).…”

Section: Icis and Anti-her-2 Targeted Therapymentioning

confidence: 93%

Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review)

Song

Guo

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates. The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort. When the symptoms become more obvious, the lesion has usually progressed to an advanced stage. Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer. These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs). With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit. Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti-vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer. This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer. The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer.

show abstract

“…Notably, for patients with HER2 amplification and PD-L1 positivity by circulating tumor DNA (ctDNA) detection, ORR was 57% and DCR was 86%. Treatment-related adverse events (TRAEs, ≥ grade 3) occurred in 13% of the patients, and serious adverse events (SAEs) included autoimmune hepatitis (two cases) and pneumonitis (one case) [69] (Table 1).…”

Section: Combination With Other Targeted Agentsmentioning

confidence: 99%

Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects

Zhou

Zhang

2019

Front. Med.

View full text Add to dashboard Cite

Strategies in comprehensive therapy for gastrointestinal (GI) cancer have been optimized in the last decades to improve patients' outcomes. However, treatment options remain limited for late-stage or refractory diseases. The efficacy of immune checkpoint inhibitors (ICIs) for treatment of refractory GI cancer has been confirmed by randomized clinical trials. In 2017, pembrolizumab was approved by the US Food and Drug Administration as the first agent for treatment of metastatic solid tumors with mismatch repair deficiency, especially for colorectal cancer. Given the different mechanisms, oncologists have focused on determining whether ICIs-based combination strategies could achieve higher efficacy than conventional therapy alone in late-stage or even front-line treatment of GI cancer. This review discusses the current status of combining immune checkpoint inhibitors with molecular targeted therapy, chemotherapy, or radiotherapy in GI cancer in terms of mechanisms, safety, and efficacy to provide basis for future research.

show abstract

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Cited by 14 publications

References 0 publications

Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies

Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies

Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review)

Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects

Contact Info

Product

Resources

About